Timing of operation in asymptomatic severe aortic stenosis

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 6, 2007, Pages 1065-1071

  Chaliki, Hari P ^a   Brown, Morgan L ^b   Sundt, Thoralf M ^b   Tajik, A Jamil ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aortic stenosis; Asymptomatic; Epidemiology; Statins; Surgery

Indexed keywords

ATORVASTATIN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; BLOOD FLOW VELOCITY; CALCIFICATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; EXERCISE TEST; HEART HEMODYNAMICS; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INCIDENCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRESSURE GRADIENT; PROGNOSIS; REVIEW; RHEUMATIC FEVER; RISK FACTOR; SURGICAL RISK; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TIME; TREATMENT INDICATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; COHORT STUDIES; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 37349003386     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.6.1065     Document Type: Review

References (43)

1. Supino PG, Borer JS, Yin A, Dillingham E, McClymont W. The epidemiology of valvular heart diseases: the problem is growing. Adv. Cardiol. 41, 9-15 (2004).
2. Nkomo VT, Gardin JM, Skelton TN et al. Burden of valvular heart diseases: a population-based study. Lancet 368(9540), 1005-1011 (2006).
3. Hughes GH, Cutter G, Donahue R et al. Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study. Control. Clin. Trials 8(Suppl. 4), 68S-73S (1987).
4. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am. J. Epidemiol. 129(4), 687-702 (1989).
5. Fried LP, Borhani NO, Enright P et al. The Cardiovascular Health Study: design and rationale. Ann. Epidemiol. 1(3), 263-276 (1991).
6. Rajamannan NM. Calcific aortic stenosis: a disease ready for prime time. Circulation 114(19), 2007-2009 (2006).
7. Garg V, Muth AN, Ransom JF et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437(7056), 270-274 (2005).
8. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101(21), 2497-2502 (2000).
9. Katz R, Wong ND, Kronmal R et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113(17), 2113-2119 (2006).
10. Briand M, Lemieux I, Dumesnil JG et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J. Am. Coll. Cardiol. 47(11), 2229-2236 (2006).
11. Messika-Zeitoun D, Bielak LF, Peyser PA et al. Aortic valve calcification: determinants and progression in the population. Arterioscler. Thromb. Vasc. Biol. 27(3), 642-648 (2007).
12. Roger VL, Tajik AJ, Reeder GS et al. Effect of Doppler echocardiography on utilization of hemodynamic cardiac catheterization in the preoperative evaluation of aortic stenosis. Mayo Clin. Proc. 71(2), 141-149 (1996).
13. Omran H, Schmidt H, Hackenbroch M et al. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet 361(9365), 1241-1246 (2003).
14. Ross J Jr, Braunwald E. Aortic stenosis. Circulation 38(Suppl. 1), 61-67 (1968).
15. Kennedy KD, Nishimura RA, Holmes DR Jr, Bailey KR. Natural history of moderate aortic stenosis. J. Am. Coll. Cardiol. 17(2), 313-319 (1991).
16. Bonow RO. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/ American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J. Am. Coll. Cardiol. 48(5), 1486-1588 (2006).
17. Otto CM, Burwash IG, Legget ME et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95(9), 2262-2270 (1997).
18. Rosenhek R, Binder T, Porenta G et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N. Engl. J. Med. 343(9), 611-617 (2000).
19. Kelly TA, Rothbart RM, Cooper CM et al. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am. J. Cardiol. 61(1), 123-130 (1988).
20. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J. Am. Coll. Cardiol. 15(5), 1012-1017 (1990).
21. Pellikka PA, Sarano ME, Nishimura RA et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111(24), 3290-3295 (2005).
22. Amato MC, Moffa PJ, Werner KE, Ramires JA. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart 86(4), 381-386 (2001).
23. Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am. Heart J. 99(4), 419-424 (1980).
24. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann. Thorac. Surg. 82(6), 2116-2122 (2006).
25. Messika-Zeitoun D, Aubry MC, Detaint D et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 110(3), 356-362 (2004).
26. Alborino D, Hoffmann JL, Fournet PC, Bloch A. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J. Heart Valve Dis. 11(2), 204-209 (2002).
27. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur. Heart J. 26(13), 1309-1313 (2005).
28. Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109(19), 2302-2308 (2004).
29. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 115(22), 2856-2864 (2007).
30. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 1291-1295 (2004).
31. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389-2397 (2005).
32. Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol. 49(5), 554-561 (2007).
33. Rossebo AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol. 99(7), 970-973 (2007).
34. Chan KL, Teo K, Tam J, Dumesnil JG. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am. Heart J. 153(6), 925-931 (2007).
35. O'Brien KD. Do bioprosthetic aortic valves deteriorate more rapidly in patients with the metabolic syndrome? Nat. Clin. Pract. Cardiovasc. Med. 4, 192-193 (2007).
36. O'Brien KD, Probstfield JL, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Int. Med. 165(8), 858-862 (2005).
37. O'Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106(17), 2224-2230 (2002).
38. Braunwald E. On the natural history of severe aortic stenosis. J. Am. Coll. Cardiol. 15(5), 1018-1020 (1990).
39. Jamieson WRE, Edwards FH, Schwartz M et al. Risk stratification for cardiac valve replacement. National Cardiac Surgery Database. Ann. Thorac. Surg. 67(4), 943-951 (1999).
40. Smith WTt, Ferguson TB Jr, Ryan T, Landolfo CK, Peterson ED. Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma. J. Am. Coll. Cardiol. 44(6), 1241-1247 (2004).
41. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 28(2), 230-268 (2007).
42. Malouf JF, Enriquez-Sarano M, Pellikka PA et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J. Am. Coll. Cardiol. 40(4), 789-795 (2002).
43. Webb JG, Chandavimol M, Thompson CR et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 113(6), 842-850 (2006).